TC BioPharm Announces Strategic Collaboration To Advance Gamma Delta T Cells In Oncology
TC BioPharm Announces Strategic Collaboration To Advance Gamma Delta T Cells In Oncology
Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings
努力專注於擴大對腫瘤環境中 γ-三角 T 細胞的理解
EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.
蘇格蘭愛丁堡，2023 年 1 月 17 日/新聞通訊/-TC 生物製藥（控股）有限公司（「TC 生物製藥」或「公司」）（NASDAQ：TCBPW），一家臨床階段生物技術公司開發用於癌症治療的平台異體伽瑪三角 T 細胞療法，今日宣布與德克薩斯州安德森大學醫學研究中心開發策略性知識 γ-三角 T 細胞如何在腫瘤學環境中工作的基礎。
The collaboration brings together MD Anderson's clinical trial infrastructure and the translational research expertise of its immunotherapy platform with the clinical data of TC BioPharm's targeted gamma-delta T cell oncology pipeline. Under the terms of the three-year agreement, the research teams will work together on both preclinical and clinical studies to evaluate the potential for gamma-delta T cell therapies and to better understand the behaviors of these cells in patients. The collaborators will form a six-person steering committee to drive the development of both the data set and subsequent assays for each study.
此次合作將 MD Anderson 的臨床試驗基礎設施和其免疫治療平台的轉化研究專業知識與 TC BioCharm 針對性 γ-三角 T 細胞腫瘤學產品線的臨床資料結合在一起。根據三年協議的條款，研究團隊將共同進行臨床前和臨床研究，以評估 γ-三角 T 細胞療法的潛力，並更好地了解這些細胞在患者中的行為。合作者將組成一個六人督導委員會，以推動每項研究的數據集和後續分析的發展。
The comprehensive immunoprofiling capabilities of MD Anderson's immunotherapy platform will enable correlative studies on clinical samples to uncover detailed insights on the behavior of gamma-delta T cells and corresponding responses in patients. The platform is co-led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology, and James Allison, Ph.D., regental chair of Immunology.
MD Anderson 免疫治療平台的全面免疫分析能力將使臨床樣本的相關研究發現，以發現有關 γ-三角 T 細胞行為和患者相應反應的詳細見解。該平台由 Padmanee Sharma，醫學博士，博士，泌尿生殖腫瘤學和免疫學教授和詹姆斯·艾利森博士，免疫學攝政主席共同領導。
Formulating a better picture of what is occurring in patients during gamma delta T cell therapies is expected to allow TC Biopharm to better design future studies as well as form a view towards future targeted cancer studies in other blood cancers and solid tumors potentially.
制定更好地了解伽瑪三角 T 細胞療法期間患者發生的情況，有望使 TC Bioharm 更好地設計未來的研究，並對未來針對其他血液癌和實體腫瘤的針對性癌症研究形成一個觀點。
"We are enthusiastic about working with MD Anderson to further our knowledge of gamma delta T cells in order to help TC Biopharm develop future trials and treatments using our platform therapy OmnImmune," said Bryan Kobel, CEO of TC BioPharm. "This collaboration reinforces our mutual commitment to accelerating the discovery and development of cell therapies, and it highlights TC Biopharm's expertise in the gamma delta T cell space."
TC BioHharm 首席執行官 Bryan Kobel 表示：「我們熱衷於與 MD Anderson 合作，以進一步了解伽瑪三角 T 細胞，以幫助 TC 生物製藥開發未來的試驗和治療方法，使用我們的平台治療全部免疫。這次合作加強了我們對加速細胞療法發現和開發的共同承諾，並強調了 TC Bioharm 在伽瑪三角 T 細胞空間方面的專業知識。」